The Zacks Analyst Blog Highlights: Microsoft, Hewlett-Packard, Google, Apple and Johnson & Johnson

CHICAGO, April 2, 2014 — (PRNewswire) — announces the list of stocks featured in the Analyst Blog. Every day the Zacks Equity Research analysts discuss the latest news and events impacting stocks and the financial markets. Stocks recently featured in the blog include the Microsoft Corp. (Nasdaq: MSFT- Free Report), Hewlett-Packard (NYSE: HPQ- Free Report), Google (Nasdaq: GOOG- Free Report), Apple (Nasdaq: AAPL- Free Report) and Johnson & Johnson (NYSE: JNJ- Free Report).

Zacks Investment Research, Inc.,

Today, Zacks is promoting its "Buy" stock recommendations. Get #1Stock of the Day pick for free.

Here are highlights from Tuesday's Analyst Blog:

Microsoft Targets 25M Tablet Shipment

Reportedly,Microsoft Corp. (Nasdaq: MSFT- Free Report) plans to ship 25 million Windows tablets by the end of this year. Additionally, the company expects its own Surface tablets shipments to increase to 6 million from 3 million in 2013.

In order to achieve this target, Microsoft plans to provide incentives to vendors manufacturing Windows tablets. Reportedly, companies including ASUStek, Acer, Hewlett-Packard (NYSE: HPQ- Free Report), Dell and Toshiba plan to ship Windows-based tablets in the near future.

Despite the drastic measures taken to counter competition in the industry, Microsoft is battling the slump in the PC market just like all the other PC makers. The company launched its first touch-based operating system — Windows 8 — in 2012. However, to add to its woes, the launch could not provide the much needed boost to the PC market.

Therefore, to bridge the gap between tablets and PCs, Microsoft upgraded its Windows operating system to Windows 8.1. The new and improved version is believed to address user complaints regarding the earlier version, Windows 8.

Despite all its efforts, Microsoft is unable to cope with the stiff competition from android and iOS tablets. As per reports from market research firm IDC, Android tablets secured the top spot with 120 million units shipped in 2013, while only 5 million Windows tablets were shipped during the same time.

In the process, Google's (Nasdaq: GOOG- Free Report) Android tablets captured 61.9% share of the tablet market. Apple's (Nasdaq: AAPL- Free Report) iOS tablets with a 36.0% share were next in line, followed by Microsoft's Windows tablets with 2.1% and others making up the rest. Microsoft is way behind competitors and scaling up its market share substantially is going to be an uphill task.

Microsoft Corporation develops, manufactures, licenses, sells and supports software products. The company operates in five segments — Windows & Windows Live Division, Server and Tools, Online Services Division, Microsoft Business Division, and Entertainment and Devices Division.

We believe Microsoft is one of the best positioned software vendors but it will have to explore ways to recover from the current situation.

Currently, Microsoft has a Zacks Rank #3 (Hold).

J&J to Sell Ortho Clinical Diagnostics Biz

Johnson & Johnson (NYSE: JNJ- Free Report) will be selling its Ortho-Clinical Diagnostics business to The Carlyle Group for about $4 billion. The company said that it has accepted the binding offer from The Carlyle Group which was announced on Jan 16.

Johnson & Johnson said that it expects the deal to go through in mid-14. We expect updates on the deal on Apr 15 when the company announces its first quarter results.

The upcoming sale of the Ortho Clinical Diagnostics business indicates Johnson & Johnson's increased focus on the pharma business which has been performing well. Johnson & Johnson reported pharmaceutical sales of $28.1 billion in 2013, up 10.9%.

Although some products in the pharma segment are facing generic competition, new products are steadily gaining traction and performing well. Some of the important and promising new products in Johnson & Johnson's portfolio include Zytiga, Invokana, Stelara, Xarelto, Simponi and Invega Sustenna. Other growth drivers include Prezista, Remicade and Velcade. We believe prostate cancer treatment, Zytiga, which posted sales of $1.7 billion in 2013, has multi-billion dollar potential.

Another product with blockbuster potential is Imbruvica. Imbruvica is approved for mantle cell lymphoma and chronic lymphocytic leukemia in patients who have received at least one prior treatment.

Today, Zacks is promoting its "Buy" stock recommendations. Get #1Stock of the Day pick for free.

About Zacks Equity Research

Zacks Equity Research provides the best of quantitative and qualitative analysis to help investors know what stocks to buy and which to sell for the long-term.

Continuous coverage is provided for a universe of 1,150 publicly traded stocks. Our analysts are organized by industry which gives them keen insights to developments that affect company profits and stock performance. Recommendations and target prices are six-month time horizons.

Zacks "Profit from the Pros" e-mail newsletter provides highlights of the latest analysis from Zacks Equity Research. Subscribe to this free newsletter today.

About Zacks is a property of Zacks Investment Research, Inc., which was formed in 1978. The later formation of the Zacks Rank, a proprietary stock picking system; continues to outperform the market by nearly a 3 to 1 margin. The best way to unlock the profitable stock recommendations and market insights of Zacks Investment Research is through our free daily email newsletter; Profit from the Pros.  In short, it's your steady flow of Profitable ideas GUARANTEED to be worth your time! Register for your free subscription to Profit from the Pros.

Get the full Report on MSFT - FREE
Get the full Report on HPQ - FREE
Get the full Report on GOOG - FREE
Get the full Report on AAPL - FREE
Get the full Report on JNJ - FREE

Follow us on Twitter:

Join us on Facebook:

Zacks Investment Research is under common control with affiliated entities (including a broker-dealer and an investment adviser), which may engage in transactions involving the foregoing securities for the clients of such affiliates.

Media Contact
Zacks Investment Research
800-767-3771 ext. 9339
Email Contact

Past performance is no guarantee of future results. Inherent in any investment is the potential for loss. This material is being provided for informational purposes only and nothing herein constitutes investment, legal, accounting or tax advice, or a recommendation to buy, sell or hold a security. No recommendation or advice is being given as to whether any investment is suitable for a particular investor. It should not be assumed that any investments in securities, companies, sectors or markets identified and described were or will be profitable. All information is current as of the date of herein and is subject to change without notice. Any views or opinions expressed may not reflect those of the firm as a whole. Zacks Investment Research does not engage in investment banking, market making or asset management activities of any securities. These returns are from hypothetical portfolios consisting of stocks with Zacks Rank = 1 that were rebalanced monthly with zero transaction costs. These are not the returns of actual portfolios of stocks. The S&P 500 is an unmanaged index. Visit for information about the performance numbers displayed in this press release.

1 | 2  Next Page »

Review Article Be the first to review this article

GIS Analyst (Dallas Police) for City of Dallas at Dallas, Texas
GIS ANALYST I.8030200 for Dallas County at DALLAS, Texas
Failure Analysis Engineer for Flextronics at Milpitas, California
Geodesign Manager for Design Workshop at Aspen, Colorado
Mechanical Engineer for Flextronics at Milpitas, California
Upcoming Events
Placekey - Coming October 2020 at United States - Oct 7, 2020
Earth Intelligence 2020 Summit. - Live Webinar at United States - Oct 22, 2020
Earth Intelligence 2020 Summit at Virtual Alexandria VA - Oct 22, 2020
IEC 61850 Global 2020 at Brussels Belgium - Oct 26 - 30, 2020
University of Denver GIS Masters Degree Online

© 2020 Internet Business Systems, Inc.
670 Aberdeen Way, Milpitas, CA 95035
+1 (408) 882-6554 — Contact Us, or visit our other sites:
AECCafe - Architectural Design and Engineering EDACafe - Electronic Design Automation TechJobsCafe - Technical Jobs and Resumes  MCADCafe - Mechanical Design and Engineering ShareCG - Share Computer Graphic (CG) Animation, 3D Art and 3D Models
  Privacy PolicyAdvertise